Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
Open Access
- 1 August 2000
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 83 (4), 431-437
- https://doi.org/10.1054/bjoc.2000.1303
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerThe Lancet, 1998
- Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.Journal of Clinical Oncology, 1997
- Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancerEuropean Journal Of Cancer, 1997
- Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.Journal of Clinical Oncology, 1997
- Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.Journal of Clinical Oncology, 1997
- Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.Journal of Clinical Oncology, 1996
- Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancerBritish Journal of Surgery, 1995
- Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trialsAnnals Of Oncology, 1995
- Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancerCancer, 1994
- Protracted Infusion of 5-FU with Weekly Low-Dose Cisplatin as Second-Line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed 5-FU MonotherapyCancer Investigation, 1991